免疫检查点LAG-3在肿瘤中的研究进展

免疫检查点抑制剂治疗是目前研究最为充分的免疫疗法之一，其基本原理即应用免疫检查点抑制剂阻断抑制信号的传递，刺激细胞毒性T淋巴细胞(CTL)的活化，诱导T淋巴细胞的抗肿瘤效应。淋巴细胞激活基因-3（LAG-3）作为免疫检查点家族的一员，是一种对 T 细胞功能有着多种生物学效应的抑制性分子，在多种类型的肿瘤浸润淋巴细胞（TIL）中高表达，参与肿瘤的免疫逃逸机制。因此，LAG-3可作为肿瘤预后的指标以及肿瘤治疗的靶点。本文对LAG-3在肿瘤中表达及功能的研究进展作一综述，并探讨LAG-3在肿瘤临床治疗上的应用前景。

Research progress of immune checkpoint LAG-3 in tumor immunotherapy

Immune checkpoint inhibition，as a kind of adequately studied immunotherapy，is based on the blocking of passing inhibiting signals，excitation the CTL and inducing T lymphocyte to produce anti-tumor effect.LAG-3 is a kind of inhibitory molecule with multiple biological effects which is fond as a member of the immune checkpoint family.It has a high expression in the tumor infiltrating lymphocytes of many kinds of tumor tissues performing the tumor immune escape.Thus，we can conclude that LAG-3 will act as an important indicator in the prognosis and therapy of tumor.This review will talk about the expression and function of LAG-3 in tumor and how it is used in therapy.